Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Thyroid gland presents a wide spectrum of tumours derived from follicular cells that range from well differentiated, papillary and follicular carcinoma (PTC and FTC, respectively), usually carrying a good prognosis, to the clinically aggressive, poorly differentiated (PDTC) and undifferentiated thyroid carcinoma (UTC).It is usually accepted that PDTC and UTC occur either de novo or progress from a pre-existing well differentiated carcinoma through a multistep process of genetic and epigenetic changes that lead to clonal expansion and neoplastic development. Mutations and epigenetic alterations in PDTC and UTC are far from being totally clarified. Assuming that PDTC and UTC may derive from well differentiated thyroid carcinomas (WDTC), it is expected that some PDTC and UTC would harbour genetic alterations that are typical of PTC and FTC. This is the case for some molecular markers (BRAF and NRAS) that are present in WDTC, PDTC and UTC. Other genes, namely P53, are almost exclusively detected in less differentiated and undifferentiated thyroid tumours, supporting a diagnosis of PDTC or, much more often, UTC. Thyroid-specific rearrangements RET/PTC and PAX8/PPARγ, on the other hand, are rarely found in PDTC and UTC, suggesting that these genetic alterations do not predispose cells to dedifferentiation. In the present review we have summarized the molecular changes associated with the two most aggressive types of thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 1×
“Telomerase activation is known to be a hallmark of cancer [69], being detected in 80 to 90% of malignant tumours [70-71].”
BackgroundBryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R. (1997) · Nature Medicine · doi:10.1038/nm1197-1271 · Cited by 1,292 · cited 1×
“Some tumours may maintain their telomeres by an alternative mechanism, telomeraseindependent, designated as ALT (alternative lengthening of telomeres), which appears to maintain telomeres through recombination based interchromosomal exchange of sequence information [72-73].”
BackgroundTelomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279 · cited 1×
“Some tumours may maintain their telomeres by an alternative mechanism, telomeraseindependent, designated as ALT (alternative lengthening of telomeres), which appears to maintain telomeres through recombination based interchromosomal exchange of sequence information [72-73].”
Background
Cited by
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898
Self-citationRingel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Self-citationTohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
“Various molecular changes within PTC cells, such as RET/PTC rearrangements, RAS and BRAF mutations [13], β-catenin mutations [14] underlie the loss of iodide uptake ability.”
Background
Metadata
- Authors
- Soares, P., Lima, J., Preto, A., Castro, P., Vinagre, J., Celestino, R., P. Couto, J., Prazeres, H., Eloy, C., Maximo, V., & Sobrinho-Simoes, M.
- Venue
- Current Genomics
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-12-01
- Volume
- 12
- Issue
- 8
- Pages
- 609-617
- ISSN
- 1389-2029 (ISSN-L)
- OpenAlex
- W2100669371
- Cited by
- 85
- References
- 3
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas. https://app.cochat.ai/papers/10.2174/138920211798120853
- The paper
- Soares, P., Lima, J., Preto, A., Castro, P., Vinagre, J., Celestino, R., P. Couto, J., Prazeres, H., Eloy, C., Maximo, V., & Sobrinho-Simoes, M. (2011). Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas. Current Genomics. https://doi.org/10.2174/138920211798120853
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.